I'm LongbridgeAI, I can summarize articles.VistaGen Therapeutics reported Q1 FY2027 revenue of $1.48 million, up from $244,000 year-over-year. The net loss narrowed to $13.03 million from $15.1 million, with adjusted loss per share improving to $0.30 from $0.47. R&D and G&A expenses decreased. Cash reserves stood at $31.7 million as of June 30, 2026, supporting operations into 2027. The company plans FDA engagement regarding a potential Phase 3 path for fasedienol following the PALISADE-4 trial results.
- VistaGen posted Q1 FY2027 revenue of USD 1.48 million, up from USD 244,000 a year earlier. * Net loss narrowed to USD 13.03 million from USD 15.1 million; loss per share improved to USD 0.3 from USD 0.47. * R&D costs edged down to USD 10.91 million from USD 11.68 million; G&A expense fell to USD 3.92 million from USD 4.37 million. * Cash, cash equivalents, and marketable securities totaled USD 31.7 million at June 30, 2026; runway expected into 2027. * FDA engagement planned this quarter on a potential Phase 3 path for fasedienol after PALISADE-4 missed its primary endpoint overall. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140832PRIMZONEFULLFEED9810348) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)